Pierrot Harvie
- Biomaterials top 5%
- Nanoparticle-Based Drug Delivery 6
- Virology top 10%
- HIV Research and Treatment 3
- Molecular Biology top 10%
- RNA Interference and Gene Delivery 11
- Advanced biosensing and bioanalysis techniques 10
- Hematology top 10%
- Genetics top 10%
- Virus-based gene therapy research 5
-
- Immunotherapy and Immune Responses 3
-
- HIV/AIDS drug development and treatment 3
-
- Microtubule and mitosis dynamics 2
- Co-authors
- Marcel B. BallyFrances M. P. WongLawrence D. MayerPaul TardiTroy O. HarasymSharon A. JohnstoneNatashia HarasymSherwin Xie
- Partner nations
- CanadaUnited StatesSweden
In The Last Decade
Pierrot Harvie
25 papers receiving 1.1k citations
Peers
Comparison fields: 5 of 82
- Biomaterials 282
- Virology 69
- Molecular Biology 833
- Hematology 106
- Genetics 220
Countries citing papers authored by Pierrot Harvie
This map shows the geographic impact of Pierrot Harvie's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Pierrot Harvie with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Pierrot Harvie more than expected).
Fields of papers citing papers by Pierrot Harvie
This network shows the impact of papers produced by Pierrot Harvie. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Pierrot Harvie. The network helps show where Pierrot Harvie may publish in the future.
Co-authorship network
The 25 scholars most cited alongside Pierrot Harvie, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | 2024 | 4 | |
| 2 | 2024 | 1 | |
| 3 | 2018 | 115 | |
| 4 | 2010 | 83 | |
| 5 | 2008 | 288 | |
| 6 | Synergistic antitumor activity observed for a fixed ratio liposome formulation of Cytarabine (Cyt):Daunorubicin (Daun) against preclinical leukemia models | 2005 | 3 |
| 7 | A novel approach to prepare a liposomal irinotecan formulations that exhibit significant therapeutic activity in vivo | 2004 | 1 |
| 8 | 2003 | 18 | |
| 9 | 2003 | 35 | |
| 10 | 2003 | 1 | |
| 11 | 2003 | 5 | |
| 12 | 2000 | 138 | |
| 13 | 1999 | 36 | |
| 14 | 1999 | 142 | |
| 15 | 1998 | 73 | |
| 16 | 1998 | 31 | |
| 17 | 1997 | 5 | |
| 18 | 1996 | 14 | |
| 19 | 1995 | 27 | |
| 20 | 1994 | 28 |
About Pierrot Harvie
Pierrot Harvie is a scholar working on Virology, Biomaterials and Infectious Diseases, having authored 25 papers that have together received 1.2k indexed citations. Recurring topics across this work include RNA Interference and Gene Delivery (11 papers), Advanced biosensing and bioanalysis techniques (10 papers), Nanoparticle-Based Drug Delivery (6 papers), Virus-based gene therapy research (5 papers), HIV Research and Treatment (3 papers), Immunotherapy and Immune Responses (3 papers), HIV/AIDS drug development and treatment (3 papers) and Microtubule and mitosis dynamics (2 papers). The work is most often cited by research in Biomaterials (282 citations), Virology (69 citations) and Molecular Biology (833 citations). Pierrot Harvie has collaborated with scholars based in Canada, United States and Sweden. Frequent co-authors include Marcel B. Bally, Frances M. P. Wong, Lawrence D. Mayer, Paul Tardi, Troy O. Harasym, Sharon A. Johnstone, Natashia Harasym, Sherwin Xie, Natalia Zisman and David Bermudes.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.